| Biomarker ID | 1316 |
| PMID | 24448834 |
| Year | 2014 |
| Biomarker | FRK [SNP: rs171866: AA versus gg/gA] |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | Blood |
| Subjects | Humans |
| Regulation | Increased risk of Progression |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 1.52 (95% CI: 1.08–2.13) |
| Effect on Pathways | Pathways include: RPS6KL1 human kinase ARCHS4 coexpression, STK33 human kinase ARCHS4 coexpression, SGK3 human kinase ARCHS4 coexpression, MAP4K5 human kinase ARCHS4 coexpression, NTRK3 human kinase ARCHS4 coexpression |
| Experiment | Progression Vs No Progression During ADT |
| Type of Biomarker | Prognostic |
| Cohort | 321 patients with localized prostate cancer who underwent radical prostatectomy (RP) as initial treatment and 605 patients with advanced prostate cancer on androgen-deprivation therapy (ADT) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.015 |
| Method Used | MALDI-TOF |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |